Results 161 to 170 of about 84,070 (269)

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population. [PDF]

Genes (Basel), 2022
Zhang F, Mu G, Liu Z, Xie Q, Zhang H, Zhou S, Wang Z, Hu K, Wang Z, Zhao X, Cui Y, Xiang Q.   +11 more
europepmc   +1 more source

Successful Treatment of Adult Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis With Etoposide Guided by Plasma Epstein–Barr Virus DNA Monitoring: A Case Report

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Hemophagocytic lymphohistiocytosis (HLH) is a life‐threatening hyperinflammatory syndrome. Epstein–Barr virus (EBV)‐associated HLH is a major subtype of secondary HLH, requiring prompt diagnosis and treatment. However, treatment is particularly challenging in patients with severe coagulopathy and hepatic dysfunction.
Kuniaki Maehara, Masuho Saburi, Katsuya Kawano, Takahiro Kusaba, Shogo Urabe, Eiichi Ohtsuka   +5 more
wiley   +1 more source

A narrative literature review on the clinical utility of activated partial thromboplastin time and anti-factor Xa activity assays in cancer patients with anticoagulant therapy. [PDF]

Transl Cancer Res
Li HX, Song LH, Chen YH, Zhao J, Zhang XF.   +4 more
europepmc   +1 more source

Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis. [PDF]

Yonago Acta Med, 2022
Kato K, Hatayama Y, Shimohiro H, Ichikawa H, Fukuda T.   +4 more
europepmc   +1 more source

Retrospective cohort study comparing activated partial thromboplastin time versus anti‐factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics

Journal of Thrombosis and Haemostasis, 2015
M. Trucco, Christoph U. Lehmann, N. Mollenkopf, M. Streiff, C. Takemoto   +4 more
semanticscholar   +1 more source

Targeting CD148 for Antithrombotic Therapy: Functional and Molecular Evaluation of AKB‐9778

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT CD148 is the primary receptor‐type protein tyrosine phosphatase (PTP) regulating platelet activation, and its inhibition has been proposed as a novel anti‐thrombotic strategy with potentially lower bleeding risk than current therapies. However, selective and potent inhibitors of CD148 are currently lacking.
Lina El Badaoui, Stipo Jurcevic, Yotis A. Senis, Alastair J. Barr   +3 more
wiley   +1 more source

Deep learning model for screening causes of activated partial thromboplastin time prolongation using clot waveform analysis at multiple wavelengths. [PDF]

Sci Rep
Matsuda M, Shimomura D, Suzuki T, Tabuchi Y, Kurono H, Nishi K, Arai N, Hoshiyama Y, Kamioka M, Moriyama M, Matsumoto T.   +10 more
europepmc   +1 more source

Comparison of Time Within Therapeutic Range Using Anti-Factor Xa Versus Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin in Children. [PDF]

J Pediatr Pharmacol Ther, 2023
Haftmann RJ, Pineda EM, Hall BA, Wilson MD, Mateev SN.   +4 more
europepmc   +1 more source

Prolonged Activated Partial Thromboplastin Time

Clinical and applied thrombosis/hemostasis, 2015
P. Ames, M. Graf, J. Archer, N. Scarpato, L. Iannaccone   +4 more
semanticscholar   +1 more source

Safety Evaluation of an Aqueous Root and Leaf Extract of Ashwagandha ( Withania somnifera )

Phytotherapy Research, Volume 40, Issue 8, Page 5030-5047, August 2026.
Sensoril, an aqueous root and leaf extract of ashwagandha showed no evidence of mutagenicity in the in vitro Ames assay, was negative in the in vitro micronucleus, in vivo mammalian bone marrow chromosome aberration assays, and was well tolerated in the rat at up to 4000 mg/kg BW/day when administered orally for a period of 90 days. The data from these
Mukesh Summan, Candace L. Doepker, Gregory P. Brorby   +2 more
wiley   +1 more source